tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Nov;18(11):e70038.
doi: 10.1111/irv.70038. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection-Increasing Community Access to Testing Program, United States, January-September 2023
Allison Avrich Ciesla[SUP] 1 2 [/SUP], Josephine Mak[SUP] 1 [/SUP], Lauren E Roper[SUP] 1 [/SUP], Katherine E Fleming-Dutra[SUP] 1 [/SUP], Zachary R Smith[SUP] 3 [/SUP], Ryan E Wiegand[SUP] 1 [/SUP], Amadea Britton[SUP] 1 [/SUP], Joseph Miller[SUP] 3 [/SUP], Ruth Link-Gelles[SUP] 1 4 [/SUP]
Affiliations
Background: On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.
Methods: Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case-control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.
Results: VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%-52%) for those aged ≥ 65 years to 61% (95% CI 41%-75%) for those aged 12-17 years.
Conclusion: Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.
Keywords: Bivalent; COVID‐19; SARS‐CoV‐2; Symptomatic Infection.
. 2024 Nov;18(11):e70038.
doi: 10.1111/irv.70038. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection-Increasing Community Access to Testing Program, United States, January-September 2023
Allison Avrich Ciesla[SUP] 1 2 [/SUP], Josephine Mak[SUP] 1 [/SUP], Lauren E Roper[SUP] 1 [/SUP], Katherine E Fleming-Dutra[SUP] 1 [/SUP], Zachary R Smith[SUP] 3 [/SUP], Ryan E Wiegand[SUP] 1 [/SUP], Amadea Britton[SUP] 1 [/SUP], Joseph Miller[SUP] 3 [/SUP], Ruth Link-Gelles[SUP] 1 4 [/SUP]
Affiliations
- PMID: 39522959
- PMCID: PMC11550894
- DOI: 10.1111/irv.70038
Background: On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.
Methods: Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case-control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.
Results: VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%-52%) for those aged ≥ 65 years to 61% (95% CI 41%-75%) for those aged 12-17 years.
Conclusion: Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.
Keywords: Bivalent; COVID‐19; SARS‐CoV‐2; Symptomatic Infection.